Actively Recruiting
Short Treatment with Omalizumab for Severe Asthma
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2024-11-07
234
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The optimal duration of the treatment by OMA remains unclear when asthma is well controlled. Data suggest that a large part of patients with well controlled asthma can discontinue OMA therapy without any asthma control deterioration or with an acceptable decrease in asthma control, therefore French experts propose that omalizumab can be given for "3 to 5 yrs if asthma remains well controlled". The costs related to OMA are high and frequent injections represent severe constraints for patients. For all these reasons, evaluating whether shortening duration of OMA therapy is feasible while maintaining acceptable asthma control is a critical point. Therefore, the aim of this study is to evaluate asthma control after OMA discontinuation after at least 33 months of treatment when asthma is well controlled.
CONDITIONS
Official Title
Short Treatment with Omalizumab for Severe Asthma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient >18 years old
- Treated with Omalizumab prescribed by a pulmonologist for at least 33 months for severe allergic asthma
- Well controlled asthma with treatment (ACT score 218) and no more than one exacerbation in the past year, defined by steroid use for at least 2 days
You will not qualify if you...
- Patient refusing to stop Omalizumab treatment
- Stopping Omalizumab for reasons other than good asthma control, such as side effects, pregnancy, or switching to another advanced asthma treatment
- Not covered by health insurance
- Under curatorship, guardianship, or judicial protection
- Poor or questionable adherence to asthma treatments
- Participating in another intervention study
- Pregnant or breastfeeding
- Refusing to sign consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Bichat-Claude Bernard
Paris, Île-de-France Region, France, 75018
Actively Recruiting
Research Team
C
Camille TAILLE, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here